Windtree Therapeutics ( (WINT) ) has released a notification of late filing.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Windtree Therapeutics, Inc. has filed a Form 12b-25 indicating it will be late in submitting its Form 10-K (Yearly Report) for the fiscal year ended December 31, 2025. The delayed filing concerns its Annual Report on Form 10-K (Yearly Report), not a Form 10-Q (Quarter Report) or Form 20-F (Yearly Report).
The company cites limited liquidity and constrained internal resources as the main reasons for the delay. Management has been heavily focused on exploring financing options and potential strategic transactions, diverting time and staff away from the completion of year-end financial statements and disclosures.
Windtree notes that these capital-raising and strategic review efforts, while necessary for its survival, have made it impractical to finalize the Form 10-K (Yearly Report) by the standard SEC deadline without unreasonable effort or expense. There is no assurance that any strategic transaction will ultimately be completed.
The company expects to file the Form 10-K (Yearly Report) on or before April 15, 2026, using the 15-calendar-day extension allowed under SEC Rule 12b-25. Investors should therefore anticipate the annual report becoming available within that extended window, barring unforeseen complications.
Windtree states that it does not anticipate any significant change in results of operations compared with the prior fiscal year, based on information available at the time of the notice. Nonetheless, these expectations are inherently forward-looking and subject to change as final year-end numbers are completed and audited.
The company affirms that all other required periodic reports over the prior 12 months have been filed on time, supporting its broader compliance posture. The notification was signed on March 31, 2026 by Chief Executive Officer Jed Latkin, underscoring executive responsibility for the delayed filing and the ongoing effort to complete the annual report.
The most recent analyst rating on (WINT) stock is a Hold with a $0.01 price target. To see the full list of analyst forecasts on Windtree Therapeutics stock, see the WINT Stock Forecast page.
Spark’s Take on WINT Stock
According to Spark, TipRanks’ AI Analyst, WINT is a Underperform.
The score is dragged down primarily by very weak financial performance (minimal revenue, large losses, heavy cash burn, and negative equity with higher debt), reinforced by strongly bearish technical signals (well below moving averages with negative momentum). Valuation provides limited offset because losses make P/E uninformative and there is no dividend yield support.
To see Spark’s full report on WINT stock, click here.
More about Windtree Therapeutics
Average Trading Volume: 464,191
Technical Sentiment Signal: Sell
Current Market Cap: $364.1K
See more data about WINT stock on TipRanks’ Stock Analysis page.